CLOV Clover Health
Clover Health (CLOV) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 88% planned / 12% discretionary
Largest single sale: $1.4M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Reynoso Jamie L. | CEO, Medicare Advantage | Sell 10b5-1 | 1,921 | $4.56 | $8.8K | 2,803,446 −0.1% of holding | |
| OLDAKOWSKI JOSEPH FRANK | VP OF FINANCE AND CONTROLLER | Sell | 3,170 | $4.64 | $14.7K | 275,897 −1.1% of holding | |
| Wai Conrad | CEO, Counterpart Health | Sell 10b5-1 | 300,000 | $4.72 | $1.4M | 1,170,056 −20.4% of holding | |
| Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 9,273 | $4.78 | $44.3K | 2,805,367 −0.3% of holding | |
| Soares Karen | Chief Legal Officer | Sell | 6,846 | $4.78 | $32.7K | 1,607,371 −0.4% of holding | |
| OLDAKOWSKI JOSEPH FRANK | VP OF FINANCE AND CONTROLLER | Sell | 20,000 | $5.16 | $103.2K | 279,067 −6.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.